Nucleic acid aptamers: clinical applications and promising new horizons.

Aptamers are a special class of nucleic acid molecules that are beginning to be investigated for clinical use. These small RNA/DNA molecules can form secondary and tertiary structures capable of specifically binding proteins or other cellular targets; they are essentially a chemical equivalent of antibodies. Aptamers have the advantage of being highly specific, relatively small in size, and non-immunogenic. Since the discovery of aptamers in the early 1990s, great efforts have been made to make them clinically relevant for diseases like cancer, HIV, and macular degeneration. In the last two decades, many aptamers have been clinically developed as inhibitors for targets such as vascular endothelial growth factor (VEGF) and thrombin. The first aptamer based therapeutic was FDA approved in 2004 for the treatment of age-related macular degeneration and several other aptamers are currently being evaluated in clinical trials. With advances in targeted-therapy, imaging, and nanotechnology, aptamers are readily considered as potential targeting ligands because of their chemical synthesis and ease of modification for conjugation. Preclinical studies using aptamer-siRNA chimeras and aptamer targeted nanoparticle therapeutics have been very successful in mouse models of cancer and HIV. In summary aptamers are in several stages of development, from pre-clinical studies to clinical trials and even as FDA approved therapeutics. In this review, we will discuss the current state of aptamers in clinical trials as well as some promising aptamers in pre-clinical development.

[1]  Siamon Gordon,et al.  Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2′F-RNA Aptamers , 2003, Journal of Virology.

[2]  P. Schellhammer,et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.

[3]  M. Sobrinho-Simões,et al.  Expression of fully and under‐glycosylated forms of MUC1 mucin in gastric carcinoma , 1998, International journal of cancer.

[4]  G. Salvesen,et al.  Neutrophil elastase and cathepsin G: structure, function, and biological control. , 1988, Advances in experimental medicine and biology.

[5]  George L. Wright,et al.  Location of prostate‐specific membrane antigen in the LNCaP prostate carcinoma cell line , 1997, The Prostate.

[6]  Y. Lin,et al.  Modified RNA sequence pools for in vitro selection. , 1994, Nucleic acids research.

[7]  Yi Lu,et al.  MRI detection of thrombin with aptamer functionalized superparamagnetic iron oxide nanoparticles. , 2008, Bioconjugate chemistry.

[8]  James R Heath,et al.  Nanotechnology and cancer. , 2008, Annual review of medicine.

[9]  K. Thompson,et al.  2'-Deoxy purine, 2'-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics. , 2006, Oligonucleotides.

[10]  T. Springer,et al.  Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Omid C Farokhzad,et al.  Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo , 2011, Proceedings of the National Academy of Sciences.

[12]  B. Sullenger,et al.  RNA aptamers as reversible antagonists of coagulation factor IXa , 2002, Nature.

[13]  Zhi-ping Zhang,et al.  Quantum dot-aptamer nanoprobes for recognizing and labeling influenza A virus particles. , 2011, Nanoscale.

[14]  Susan M Lea,et al.  Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. , 2005, RNA.

[15]  J. Sennello,et al.  In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. , 1997, Chemistry & biology.

[16]  J. Koropatnick,et al.  Antisense treatment in human prostate cancer and melanoma. , 2010, Current cancer drug targets.

[17]  Ying-Fon Chang,et al.  Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein* , 2001, The Journal of Biological Chemistry.

[18]  B. Hicke,et al.  Escort aptamers: a delivery service for diagnosis and therapy. , 2000, The Journal of clinical investigation.

[19]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[20]  Sergey N Krylov,et al.  Aptamer-facilitated biomarker discovery (AptaBiD). , 2008, Journal of the American Chemical Society.

[21]  Robert Langer,et al.  Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. , 2007, Biomaterials.

[22]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[23]  P. Bates,et al.  Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding* , 1999, The Journal of Biological Chemistry.

[24]  A. Perkins,et al.  Anti-MUC1 aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice. , 2009, Nuclear medicine and biology.

[25]  H. Erickson,et al.  Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. , 1989, Annual review of cell biology.

[26]  Nebojsa Janjic,et al.  Inhibitory DNA ligands to platelet-derived growth factor B-chain. , 1996, Biochemistry.

[27]  G. Robinson,et al.  Combination therapy for the treatment of ocular neovascularization , 2007, Angiogenesis.

[28]  T. DeWeese,et al.  Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. , 2011, The Journal of clinical investigation.

[29]  M. B. Sultan,et al.  A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. , 2011, Ophthalmology.

[30]  B. Cosmi ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. , 2009, Current opinion in molecular therapeutics.

[31]  Paula J. Bates,et al.  AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin , 2006, Molecular Cancer Therapeutics.

[32]  A. Perkins,et al.  Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. , 2007, Bioconjugate chemistry.

[33]  H. Anders,et al.  Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes , 2009, Diabetologia.

[34]  Todd M. Allen,et al.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. , 2011, The Journal of clinical investigation.

[35]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[36]  K. Thompson,et al.  Pharmacokinetics and Biodistribution of Novel Aptamer Compositions , 2004, Pharmaceutical Research.

[37]  Onkar Kulkarni,et al.  Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. , 2007, Journal of the American Society of Nephrology : JASN.

[38]  J. Bártková,et al.  A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM‐3 is selectively exposed in a range of primary carcinomas , 1989, International journal of cancer.

[39]  J. Rossi,et al.  An Aptamer-siRNA Chimera Suppresses HIV-1 Viral Loads and Protects from Helper CD4+ T Cell Decline in Humanized Mice , 2011, Science Translational Medicine.

[40]  D. Miller,et al.  Tenascin expression in astrocytomas correlates with angiogenesis. , 1995, Cancer research.

[41]  Omid C. Farokhzad,et al.  Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.

[42]  Sung Ho Ryu,et al.  A Nucleolin-Targeted Multimodal Nanoparticle Imaging Probe for Tracking Cancer Cells Using an Aptamer , 2010, Journal of Nuclear Medicine.

[43]  S. Steinhubl,et al.  Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease , 2008, Circulation.

[44]  H. Anders,et al.  Cardiovascular , Pulmonary and Renal Pathology Late Onset of Ccl 2 Blockade with the Spiegelmer mNOX-E 36 – 3 PEG Prevents Glomerulosclerosis and Improves Glomerular Filtration Rate in db / db Mice , 2010 .

[45]  Andrew D. Ellington,et al.  Aptamer mediated siRNA delivery , 2006, Nucleic acids research.

[46]  D. S. Coffey,et al.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.

[47]  Kemin Wang,et al.  Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration , 2011, Proceedings of the National Academy of Sciences.

[48]  N. Bander Technology Insight: monoclonal antibody imaging of prostate cancer , 2006, Nature Clinical Practice Urology.

[49]  Volker A. Erdmann,et al.  Mirror-design of L-oligonucleotide ligands binding to L-arginine , 1996, Nature Biotechnology.

[50]  L. J. Maher,et al.  Selection and Characterization of an RNA Decoy for Transcription Factor NF-κB† , 1999 .

[51]  Keryn A Williams,et al.  Inhibitors of ocular neovascularization: promises and potential problems. , 2005, JAMA.

[52]  C. Vargeese,et al.  Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. , 1995, Biochemistry.

[53]  Ying-Fon Chang,et al.  Tumor targeting by an aptamer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[55]  Anthony D. Keefe,et al.  Aptamers as therapeutics , 2010, Nature Reviews Drug Discovery.

[56]  Xin Li,et al.  Identification of Thioaptamer Ligand against E-Selectin: Potential Application for Inflamed Vasculature Targeting , 2010, PloS one.

[57]  John O Trent,et al.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. , 2009, Experimental and molecular pathology.

[58]  D. Wagner,et al.  Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779 , 2009, Journal of thrombosis and haemostasis : JTH.

[59]  A. Bhattacharyya,et al.  Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. , 1991, Human pathology.

[60]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[61]  S D Jayasena,et al.  High-affinity and specific recognition of human thyroid stimulating hormone (hTSH) by in vitro-selected 2'-amino-modified RNA. , 1996, Nucleic acids research.

[62]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[63]  J. Kasprzak,et al.  A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. , 2011, American heart journal.

[64]  J. M. Healy,et al.  First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers , 2007, Circulation.

[65]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Sandra J. Gendler MUC1, The Renaissance Molecule , 2001, Journal of Mammary Gland Biology and Neoplasia.

[67]  R A Bendele,et al.  Derivation of RNA aptamer inhibitors of human complement C5. , 1999, Immunopharmacology.

[68]  Nihal Ahmad,et al.  Silencing of polo‐like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  E. Spicer,et al.  The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. , 2008, Cancer research.

[70]  T. Minko,et al.  Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[71]  R. Langer,et al.  Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. , 2010, Nanomedicine.

[72]  Y. Chung,et al.  Alterations of O-glycan biosynthesis in human colon cancer tissues. , 1994, Glycobiology.

[73]  John J Rossi,et al.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[74]  C. Ferreira,et al.  DNA Aptamers That Bind to MUC1 Tumour Marker: Design and Characterization of MUC1-Binding Single-Stranded DNA Aptamers , 2006, Tumor Biology.

[75]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[76]  L. Gold,et al.  Post-SELEX combinatorial optimization of aptamers. , 1997, Bioorganic & medicinal chemistry.

[77]  I. Brockhausen,et al.  Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. , 1995, European journal of biochemistry.

[78]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[79]  Eli Gilboa,et al.  Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication , 1990, Cell.

[80]  W. Halfter,et al.  Induction of tenascin in healing wounds , 1988, The Journal of cell biology.

[81]  S. Ringquist,et al.  Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. , 2000, Antisense & nucleic acid drug development.

[82]  N. Janjić,et al.  Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. , 1995, Chemistry & biology.

[83]  Volker A Erdmann,et al.  Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. , 2004, Nucleic acids research.